Tempus AI Shares Rise on Launch of Cancer-Profiling Device

Jan 15, 2025 · Tempus AI shares were up 14%, to $36.42, after the company launched its FDA-approved in vitro diagnostic device, xT CDx. The healthcare technology company said …

CouponFollow Extension

14%
OFF

Tempus AI Shares Rise On Launch Of Cancer-Profiling Device

2 weeks from now

Jan 15, 2025 · Tempus AI shares were up 14%, to $36.42, after the company launched its FDA-approved in vitro diagnostic device, xT CDx. The healthcare technology company said …

marketwatch.com

14%
OFF

Tempus AI Stock Soars 14% After FDA Approval Of XT CDx Test

2 weeks from now

Jan 15, 2025 · Tempus AI, a leader in healthcare technology, has unveiled its FDA-approved in vitro diagnostic device, xT CDx, marking a pivotal step forward in precision oncology.The …

business-news-today.com

14%
OFF

Tempus AI Shares Rise On Launch Of Cancer-Profiling Device

2 weeks from now

Tempus AI shares were up 14%, ... Tempus AI Shares Rise on Launch of Cancer-Profiling Device. Dow Jones 00:09. By Chris Wack Tempus AI shares were up 14%, to $36.42, after …

laohu8.com

12%
OFF

Tempus AI Shares Rise 12% On Launch Of Cancer-Profiling Device

2 weeks from now

TempusAI shares were up 14%, to $36.42, after the company launched its FDA-approved in vitro diagnostic device, xT CDx. The healthcare technology company said Wednesday that,

moomoo.com

7%
OFF

Tempus AI Inc. Stock Quote (U.S.: Nasdaq) - MarketWatch

2 weeks from now

3 days ago · Tempus AI Shares Rise on Launch of Cancer-Profiling Device Jan. 15, 2025 at 11:09 a.m. ET Tempus AI Shares Fall 11.7% After 4Q Revenue Projections Fall Below Expectations

marketwatch.com

35%
OFF

Here's Why This Medical AI Stock Soared 35% On Tuesday

2 weeks from now

Jan 21, 2025 · Shares of Tempus AI had their best day on record on Tuesday after the company launched an AI-powered health concierge. The stock also got a boost from former House …

investopedia.com

$34.92
OFF

Why Tempus AI (TEM) Is Among Wednesday’s Top Gainers?

2 weeks from now

Tempus AI, Inc (NASDAQ:TEM), an American health technology company, saw its shares rise by 9.71 percent to end at $34.92 apiece on Wednesday as investors cheered the launch of its …

yahoo.com

$400
OFF

The IPO Buzz: Cancer-Focused Tempus AI (TEM Proposed) Leads

2 weeks from now

Jun 9, 2024 · Tempus AI (TEM Proposed), known for its proprietary AI-driven healthcare data platform, leads the IPO Calendar for the second week of June with its $400 million IPO. The …

iposcoop.com

FAQs about Tempus AI Shares Rise on Launch of Cancer-Profiling Device Coupon?

What is Tempus XT CDX?

Tempus AI (TEM) announced the national launch of the company’s FDA-approved, NGS-based in vitro diagnostic device, xT CDx. Beginning today, xT C... ...

Why is Tempus AI (TEM) Wednesday's top gainer?

Why Tempus AI (TEM) is Wednesday’s Top Gainer? Copyright: nexusplexus / 123RF Stock Photo Tempus AI, Inc (NASDAQ:TEM), an American health technology company, saw its shares rise by 9.71 percent to end at $34.92 apiece on Wednesday as investors cheered the launch of its FDA-approved in vitro diagnostic device called xT CDx. ...

Is Tempus AI (tem) a good stock to buy?

Tempus AI (NASDAQ:TEM) said the xT CDx is now available for orders within the US. Overall, TEM ranks 9th on our list of Wednesday’s top gainers that lead rally. ...

Is Tempus AI stock up 40% in January?

Tempus AI Stock Is Up 40% in January. Is It Too Late to Buy? What's Going On With Tempus AI Shares Wednesday? TEM | Complete Tempus AI Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. ...

Does Tempus AI have a partnership with Genialis?

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based algorithms across cancer types. ...

Is Tempus a good treatment for cancer?

Tempus is presenting the results of its validation study at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting, which demonstrated that IPS-High patients in the study were more likely to have an overall survival benefit while receiving ICI-based therapy than IPS-Low patients in the study (HR 0.45). ...